Moderna's "mRNA Personalized Vaccine" Succeeds for First Time, Chinese Innovative Drugs Queue Up

Moderna's Phase III clinical trial has for the first time validated the tumor treatment value of mRNA personalized cancer vaccines in a large-scale trial, with Citi naming Chinese players as ones to watch. Hengrui's Ruihongdi RGL-270 has entered Phase II with promising pancreatic cancer data, CSPC's SYS6026 is advancing steadily with a controlled design, while Akeso, CanSino, and Clover each hold differentiated positions—a Chinese race in mRNA cancer vaccines has officially begun.